Quantum Dot loaded BQCA‐Octadecylamine conjugate nanosystems for theranostic applications in Alzheimer’s Disease.

Alzheimer’s Disease (AD) is one of the most common types of dementias in the world and is characterized by progressive, irreversible neurodegeneration. Benzyl quinolone carboxylic acid was shown to have beneficial in management of AD. The current challenge with BQCA is its low brain half‐life, permeability and rapid elimination. The above challenge can be answered by formulating lipid drug conjugates of BQCA, with octadecyl amine (BQCA‐ODA). Quantum dots (QDs) with their unique optical properties, with high sensitivity and stability emerging as theranostic agents in several neurodegenerative diseases. Hypothesizing the co‐delivery of QDs and BQCA for the effective treatment of AD, in the present study we have formulated lipid nano carriers loaded with quantum dots (QDs) surface modified with Polysorbate 80, called PS80‐QD‐BQCA‐ODA‐NPs, for integrating imaging and therapy for effective management of AD.